Unknown

Dataset Information

0

Emerging immune targets for the treatment of multiple myeloma.


ABSTRACT: We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24%. Other monoclonal antibodies that have shown efficacy in combination therapy include siltuximab (OR: 66%), indatuximab (OR: 78%), isatuximab (OR: 64.5%), pembrolizumab (OR: 60%), bevacizumab (OR: 70%), dacetuzumab (OR: 39%) and lorvotuzumab (OR: 56.4%). No OR was observed with monotherapy using BI-505, siltuximab, bevacizumab, AVE-1642, figitumumab, atacicept, milatuzumab, dacetuzumab, lucatumumab, IPH2101, lorvotuzumab, BT062 and nivolumab. We included seven clinical trials on chimeric antigen receptor (CAR) T cells. CAR T-cell targets include BCMA, CD19, KLC and CD138. A recent experience of CAR T-cell (B-cell maturation antigen) therapy in advanced MM has shown global response of 100%. The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising.

SUBMITTER: Sohail A 

PROVIDER: S-EPMC5810847 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Emerging immune targets for the treatment of multiple myeloma.

Sohail Atif A   Mushtaq Adeela A   Iftikhar Ahmad A   Warraich Zabih Z   Kurtin Sandra E SE   Tenneti Pavan P   McBride Ali A   Anwer Faiz F  

Immunotherapy 20180201 4


We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24%. Other monoclonal antibodies that have shown efficacy in combination therapy include siltuximab (OR: 66%), indatuximab (OR: 78%), isatuximab (OR: 64.5%), pembrolizumab (OR: 60%), bevacizumab (OR: 70%), dacetuzumab (OR: 39%) and lorvotuzumab (OR: 56.4%). No OR was observed with monotherapy usin  ...[more]

Similar Datasets

| S-EPMC6142613 | biostudies-literature
| S-EPMC3183751 | biostudies-other
| S-EPMC7060936 | biostudies-literature
| S-EPMC6582283 | biostudies-literature
| S-EPMC9468480 | biostudies-literature
| S-EPMC3080785 | biostudies-literature
| S-EPMC7654052 | biostudies-literature
| S-EPMC8246813 | biostudies-literature
| S-EPMC4969594 | biostudies-literature
| S-EPMC5215047 | biostudies-literature